3 ms·
Calico has a very strange pipeline of drugs that don't have much in common. The last paper about Yamamaca factors looked quite interesting, but Altos is much mo
by xiphias2 5y ago
Calico has a very strange pipeline of drugs that don't have much in common. The last paper about Yamamaca factors looked quite interesting, but Altos is much more focused on understanding just that one technology. Other successful new companies are platform companies, which Calico isn't.
- wantsanagent 5y ago*Yamanaka https://en.wikipedia.org/wiki/Shinya_Yamanaka https://en.wikipedia.org/wiki/Shinya_Yamanaka
- sangnoir 5y ago> Calico has a very strange pipeline of drugs that don't have much in common Aren't they all related to fighting the effects of aging, which is the company mission? I've observed that when some people have solved their money problems, the next challenge they face is their own aging and mortality - so they try to solve for that too.
- xiphias2 5y agoThis is true, I'm also in that category of people: I'm rich enough that money is not a problem for me, but too poor to invest in solving aging meaningfully. What Calico didn't get right is that it was super secretive for a long time and not collaborated with the underfunded antiaging community. It got better in the last few years, but I have much more hopes for Altos (and I really hope people there push back on being secretive on something, where making the highest possible return is not the most important goal for the investors).